On the same day that it announced a shift in its corporate strategy, Teva Pharmaceutical Industries Ltd. struck a deal for the global rights to Xenon Pharmaceuticals Inc.’s pain drug XEN-402.
The deal fits nicely into the Israeli generics company’s more focused approach to R&D, which includes an increased emphasis on central nervous system (including pain and neurodegenerative disorders) and respiratory diseases, while toning down activities in